Heparin-induced thrombocytopenia: natural history, diagnosis, and management

Review published in Vasc Med (2001)

Última actualización: June 18, 2026Revisado por: ASH Editorial Board

Research article — evidence reviewArticle reference

Evidence: Narrative reviewDesarrollo de fármacosEnsayos clínicosDeitcher SR, Carman TL · Vascular medicine, 2001

Abstract

Heparin-induced thrombocytopenia (HIT) is an under-recognized, limb- and life-threatening complication of pharmacologic heparin administration. Antibody formation against heparin complexed to platelet factor 4 (PF4) is central to the pathogenesis of HIT. Heparin:PF4 antibodies promote platelet activation and aggregation as well as excess thrombin generation which may lead to clinical thrombosis. HIT should be suspected in patients who develop thrombocytopenia with or without associated arterial or venous thrombosis while on heparin. HIT is a clinical diagnosis. Specialized HIT assays should be interpreted with care. The cornerstone of HIT management is the discontinuation of all forms of heparin exposure and the institution of anticoagulation with an alternative agent. The direct thrombin inhibitors lepirudin and argatroban are currently available and approved for use in patients with HIT.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Publication typeJournal ArticleReview

Indexed MeSH termsAnticoagulantsHeparinHumansThrombocytopenia

Resumen

HIT review emphasizing PF4-heparin antibody pathogenesis and FDA-approved lepirudin and argatroban DTIs for HIT thrombosis management.

Por qué esto importa para la hirudoterapia

This review discusses the diagnosis and management of heparin-induced thrombocytopenia (HIT), described as a serious complication of heparin therapy caused by antibodies against heparin complexed to platelet factor 4 that promote platelet activation and excess thrombin generation. The abstract identifies direct thrombin inhibitors lepirudin and argatroban as currently available and approved alternative anticoagulants for HIT management, following discontinuation of all heparin exposure. While lepirudin is named as a treatment option, the abstract contains no mention of leeches, hirudin, or the leech secretome. No defensible leech or hirudotherapy connection can be drawn from the abstract alone; the article is focused on clinical HIT management.

Citación

Heparin-induced thrombocytopenia: natural history, diagnosis, and management.

Deitcher SR, Carman TL · Vascular medicine, 2001

Contexto clínico relacionado

Explore cómo esta investigación se conecta con la práctica clínica

Drug Pipeline Drug Development Direct Thrombin Inhibitors Clinical Evidence Clinical Applications Otolaryngology

Aviso legal — investigación y educación

La información en esta página se proporciona únicamente con fines educativos e informativos y no constituye asesoramiento médico, diagnóstico o recomendaciones de tratamiento. Los resúmenes de evidencia clínica reflejan la literatura publicada revisada por pares y no implican eficacia terapéutica fuera de los contextos autorizados por la FDA.

La autorización FDA 510(k) para sanguijuelas medicinales se limita a indicaciones específicas. Las aplicaciones en investigación y fuera de indicación se identifican como tales. Los profesionales deben consultar las directrices vigentes de la FDA, los protocolos institucionales y las normativas estatales aplicables antes del uso clínico.

ASH apoya la evaluación rigurosa basada en evidencia de todas las aplicaciones de hirudoterapia mediante ensayos clínicos controlados e investigación revisada por pares.

Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: June 18, 2026